Duchenne Muscular Dystrophy is a severe and progressive neuromuscular disorder that currently has no cure. However, advancements in the Duchenne Muscular Dystrophy Therapeutics Market are driving innovation, offering new hope to patients and their families. Researchers and pharmaceutical companies worldwide are actively working to develop groundbreaking therapies aimed at slowing...

NK-cell lymphoma is a rare and aggressive cancer that originates in natural killer (NK) cells—immune system components responsible for targeting infected or malignant cells. The most prevalent subtype, extranodal NK/T-cell lymphoma, nasal type (ENKL), primarily affects the nasal region but can also involve the skin, gastrointestinal tract, and lymph nodes. Given its aggressive progression...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons, leading to muscle weakness, paralysis, and ultimately respiratory failure. The disease is often fatal within 3 to 5 years of diagnosis. Though the prevalence of amyotrophic lateral sclerosis is relatively low, with approximately 2 per 100,000 people affected annually, it continues to pose...

  The trastuzumab biosimilar market has emerged as a significant segment within the global biopharmaceutical industry. Trastuzumab, originally marketed under the brand name Herceptin by Roche, is an essential treatment for HER2-positive breast cancer and gastric cancer. As patents for the drug expired, biosimilars—medications that are highly similar but not identical to the reference...

Gene therapy is emerging as a groundbreaking approach in the Duchenne muscular dystrophy treatment landscape, offering hope for patients affected by this progressive neuromuscular disorder. With ongoing research and clinical trials, scientists are working toward developing long-term and potentially curative solutions. Duchenne Muscular Dystrophy Epidemiology Duchenne muscular...